Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Yi Miao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1799-1448; OpenAlex author ID A5018556256, A5112770347. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2013: 4 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 7 papers · 2026: 2 papers

Papers 26

  1. Editorial Expression of Concern: SATB1 Promotes Pancreatic Cancer Growth and Invasion Depending on MYC Activation. Co-author DOI 10.1007/s10620-026-10211-5↗
  2. Symptom associations during early recovery after pancreatic cancer surgery: an exploratory cross-sectional network analysis. Co-author DOI 10.1186/s12885-026-16383-7↗
  3. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Co-author DOI 10.1002/wjs.12630↗
  4. Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. Co-author DOI 10.1016/j.omton.2025.201080↗
  5. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Co-author DOI 10.1038/s41416-025-03061-x↗
  6. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-025-07740-8↗
  7. The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Co-author DOI 10.1186/s12885-025-14262-1↗
  8. Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/… Last author DOI 10.1186/s12943-025-02326-6↗
  9. [Retracted] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2025.13475↗
  10. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance. Co-author DOI 10.1007/s10495-023-01901-w↗
  11. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer. Last author DOI 10.1002/mc.23627↗
  12. Translation and validation of the Pancreatic Cancer Disease Impact score for Chinese patients with pancreatic cancer: A methodological and cross-sectional stud… Co-author DOI 10.1016/j.apjon.2023.100209↗
  13. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  14. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Co-author DOI 10.1186/s12943-022-01636-3↗
  15. [Corrigendum] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2022.12738↗
  16. LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.3389/fcell.2021.647387↗
  17. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  18. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Co-author DOI 10.1016/j.canlet.2019.04.022↗
  19. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Co-author DOI 10.1016/j.prp.2019.152666↗
  20. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗
  21. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Last author DOI 10.3892/or.2017.6036↗
  22. hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Last author DOI 10.3892/ijo.2013.2189↗
  23. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Last author DOI 10.1016/j.canlet.2012.11.005↗
  24. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric … Last author DOI 10.1186/1479-5876-11-262↗
  25. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer. Last author DOI 10.3760/cma.j.issn.0366-6999.20130748↗
  26. CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Last author DOI 10.3892/ijo.2013.2015↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 15 shared papers, 2013–2025 · strength 1.95
  2. Jishu Wei · 7 shared papers, 2013–2025 · strength 1.02
  3. Zipeng Lu · 7 shared papers, 2013–2025 · strength 0.88
  4. Qun Chen · 5 shared papers, 2020–2025 · strength 0.82
  5. Xumin Huang · 4 shared papers, 2022–2025 · strength 0.82
  6. Lingdong Meng · 4 shared papers, 2022–2025 · strength 0.73
  7. Peng Shen · 4 shared papers, 2022–2025 · strength 0.73
  8. Hao Yuan · 5 shared papers, 2019–2025 · strength 0.71
  9. Baobao Cai · 7 shared papers, 2013–2025 · strength 0.69
  10. Yunpeng Peng · 4 shared papers, 2013–2025 · strength 0.66
  11. Xinchun Liu · 4 shared papers, 2017–2025 · strength 0.66
  12. Guodong Shi · 5 shared papers, 2019–2025 · strength 0.63
  13. Zekuan Xu · 4 shared papers, 2013–2026 · strength 0.61
  14. Wanli Ge · 3 shared papers, 2022–2025 · strength 0.60
  15. Junli Wu · 6 shared papers, 2013–2025 · strength 0.60
  16. Kuirong Jiang · 4 shared papers, 2013–2025 · strength 0.59
  17. Jingjing Zhang · 2 shared papers, 2025 · strength 0.47
  18. Xinjian Liu · 3 shared papers, 2019–2025 · strength 0.44
  19. Guangfu Li · 3 shared papers, 2019–2025 · strength 0.44
  20. Min Tu · 3 shared papers, 2013–2025 · strength 0.42
  21. Ying Xin · 2 shared papers, 2022–2025 · strength 0.41
  22. Bin Chen · 2 shared papers, 2022–2025 · strength 0.41
  23. Lei Chen · 3 shared papers, 2019–2025 · strength 0.41
  24. Shangnan Dai · 2 shared papers, 2023–2024 · strength 0.40
  25. Ningning Xia · 1 shared paper, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.